Licensed use — if any
No authorised human therapeutic indication is presented. In July 2026, an FDA advisory committee reviewed nominated BPC-157 bulk substances for ulcerative colitis compounding.
Experimental 15-amino-acid peptide
An experimental peptide widely promoted online for tissue and gastrointestinal recovery, despite the gap between preclinical research and proven human treatment.
No authorised human therapeutic indication is presented. In July 2026, an FDA advisory committee reviewed nominated BPC-157 bulk substances for ulcerative colitis compounding.
Preclinical models of gastrointestinal injury, inflammation and tissue repair. These models do not establish clinical effectiveness in people.
Evidence lens
The strongest claim on the page should never be stronger than the strongest source behind it.
Regulatory snapshot
No UK treatment claim is made. Verify the current medicines status with MHRA before any clinical presentation or supply.
Not FDA approved; FDA has identified significant safety concerns in the compounding review process.
BPC-157 is prohibited under WADA S0 as a non-approved substance.
Primary sources
Statuses change. Always check the current regulator, product label, trial record and anti-doping list.
Do not start, stop or source a medicine based on this page. Speak to a qualified healthcare professional and use regulated supply routes. Call 999 in an emergency or NHS 111 for urgent advice.
Continue through the library →